BRAF mutations have been associated with downstream mutational signaling pathways mediated by BRAF, which have garnered significant interest among researchers.[33] Several meta-analyses have been conducted to investigate mutations in papillary thyroid cancer, colorectal cancer, and melanoma, revealing a strong correlation between BRAF mutations and specific pathological parameters such as tumor histology, clinical stage, gender, and smoking status.[34,36] The research findings have shed light on the substantial impact of BRAF mutations on the clinical characteristics of NSCLC. The gene discussed is BRAF; the disease is neoplasm.